{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:44:13Z","timestamp":1778935453427,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Gastroenterol"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s12664-015-0576-1","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T19:38:06Z","timestamp":1438717086000},"page":"286-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis"],"prefix":"10.1007","volume":"34","author":[{"given":"Sundeep Kumar","family":"Goyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod Kumar","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneet Kumar","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayant","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manas","family":"Behera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arttrika","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok Kumar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,6]]},"reference":[{"key":"576_CR1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","volume":"11","author":"D Lavanchy","year":"2004","unstructured":"Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97\u2013107.","journal-title":"J Viral Hepat"},{"key":"576_CR2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582\u201392.","journal-title":"Lancet"},{"key":"576_CR3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1743-422X-5-156","volume":"5","author":"S Datta","year":"2008","unstructured":"Datta S. An overview of molecular epidemiology of hepatitis B virus (HBV) in India. Virol J. 2008;5:156.","journal-title":"Virol J"},{"key":"576_CR4","doi-asserted-by":"crossref","unstructured":"McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49 Suppl:S45\u2013S55.","DOI":"10.1002\/hep.22898"},{"key":"576_CR5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3748\/wjg.v13.i6.830","volume":"13","author":"GY Wu","year":"2007","unstructured":"Wu GY, Chen HS. Novel approaches towards conquering hepatitis B infection. World J Gastroenterol. 2007;13:830\u20136.","journal-title":"World J Gastroenterol"},{"key":"576_CR6","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","volume":"125","author":"AS Lok","year":"2003","unstructured":"Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714\u201322.","journal-title":"Gastroenterology"},{"key":"576_CR7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661\u20132.","journal-title":"Hepatology"},{"key":"576_CR8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association for the Study of the Liver","year":"2012","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201385.","journal-title":"J Hepatol"},{"key":"576_CR9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531\u201361.","journal-title":"Hepatol Int"},{"key":"576_CR10","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886\u201393.","journal-title":"Hepatology"},{"key":"576_CR11","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521\u201331.","journal-title":"N Engl J Med"},{"key":"576_CR12","first-page":"1419","volume":"38","author":"ER Schiff","year":"2003","unstructured":"Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003;38:1419\u201327.","journal-title":"Hepatology"},{"key":"576_CR13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","volume":"13","author":"E Schiff","year":"2007","unstructured":"Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13:349\u201360.","journal-title":"Liver Transpl"},{"key":"576_CR14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/MCG.0b013e318214ab5d","volume":"45","author":"SG Lim","year":"2011","unstructured":"Lim SG, Aung MO, Mak B, et al. Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. J Clin Gastroenterol. 2011;45:818\u201323.","journal-title":"J Clin Gastroenterol"},{"key":"576_CR15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","volume":"52","author":"JH Shim","year":"2010","unstructured":"Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52:176\u201382.","journal-title":"J Hepatol"},{"key":"576_CR16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","volume":"53","author":"YS Liaw","year":"2011","unstructured":"Liaw YS, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62\u201372.","journal-title":"Hepatology"},{"key":"576_CR17","doi-asserted-by":"crossref","first-page":"A202","DOI":"10.1111\/j.1440-1746.2008.05772.x","volume":"24","author":"JTPC Kao","year":"2009","unstructured":"Kao JTPC, Lai HC, Chuang PH, et al. Efficacy of entecavir in naive patients with chronic hepatitis B and decompensated liver cirrhosis. J Gastroenterol Hepatol. 2009;24:A202.","journal-title":"J Gastroenterol Hepatol"},{"key":"576_CR18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","volume":"54","author":"YS Liaw","year":"2011","unstructured":"Liaw YS, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: randomized, open label study. Hepatology. 2011;54:91\u2013100.","journal-title":"Hepatology"},{"key":"576_CR19","first-page":"514A","volume":"50","author":"AM Pellicelli","year":"2009","unstructured":"Pellicelli AM, Barbarini G, Romano M, et al. Entecavir therapy for lamivudine resistant HBV cirrhotic patients waiting for OLT: viral and biochemical outcomes at one year. Hepatology. 2009;50:514A.","journal-title":"Hepatology"},{"key":"576_CR20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cgh.2012.10.003","volume":"11","author":"S Koklu","year":"2013","unstructured":"Koklu S, Tuna Y, Gulsen MT, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11:88\u201394.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"576_CR21","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.antiviral.2013.08.020","volume":"100","author":"M Srivastava","year":"2013","unstructured":"Srivastava M, Rungta S, Dixit VK, Shukla SK, Singh TB, Jain AK. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. Antiviral Res. 2013;100:300\u20135.","journal-title":"Antiviral Res"},{"key":"576_CR22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468\u201375.","journal-title":"Lancet"},{"key":"576_CR23","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2012.01.044","volume":"142","author":"SJ Scaglione","year":"2012","unstructured":"Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360\u20138.","journal-title":"Gastroenterology"},{"key":"576_CR24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","volume":"49","author":"DJ Tenney","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503\u201314.","journal-title":"Hepatology"},{"key":"576_CR25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001\u201310.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"576_CR26","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lt.21615","volume":"14","author":"F Zoulim","year":"2008","unstructured":"Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transplant. 2008;14 Suppl 2:S1\u20137.","journal-title":"Liver Transplant"},{"key":"576_CR27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","volume":"34","author":"FY Yao","year":"2001","unstructured":"Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001;34:411\u20136.","journal-title":"Hepatology"},{"key":"576_CR28","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","volume":"53","author":"GV Papatheodoridis","year":"2010","unstructured":"Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348\u201356.","journal-title":"J Hepatol"},{"key":"576_CR29","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2036.2011.04990.x","volume":"35","author":"AK Singal","year":"2012","unstructured":"Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther. 2012;35:674\u201389.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Indian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-015-0576-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12664-015-0576-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12664-015-0576-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T09:49:48Z","timestamp":1559468988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12664-015-0576-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["576"],"URL":"https:\/\/doi.org\/10.1007\/s12664-015-0576-1","relation":{},"ISSN":["0254-8860","0975-0711"],"issn-type":[{"value":"0254-8860","type":"print"},{"value":"0975-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}